BRPI0109494B8 - muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii - Google Patents

muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii

Info

Publication number
BRPI0109494B8
BRPI0109494B8 BRPI0109494A BR0109494A BRPI0109494B8 BR PI0109494 B8 BRPI0109494 B8 BR PI0109494B8 BR PI0109494 A BRPI0109494 A BR PI0109494A BR 0109494 A BR0109494 A BR 0109494A BR PI0109494 B8 BRPI0109494 B8 BR PI0109494B8
Authority
BR
Brazil
Prior art keywords
factor viii
viii mutein
vector
dna sequence
factor
Prior art date
Application number
BRPI0109494A
Other languages
English (en)
Portuguese (pt)
Other versions
BRPI0109494B1 (pt
BR0109494A (pt
Inventor
Hoerster Andrea
Schroeder Carola
Hauser Charlotte
Lehnerer Michael
Original Assignee
Octagene Gmbh
Octapharma Ag
Octapharma Biopharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Octagene Gmbh, Octapharma Ag, Octapharma Biopharmaceuticals Gmbh filed Critical Octagene Gmbh
Publication of BR0109494A publication Critical patent/BR0109494A/pt
Publication of BRPI0109494B1 publication Critical patent/BRPI0109494B1/pt
Publication of BRPI0109494B8 publication Critical patent/BRPI0109494B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0109494A 2000-03-22 2001-03-21 muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii BRPI0109494B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
EP00106225.6 2000-03-22
US20324900P 2000-05-08 2000-05-08
US60/203,249 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (en) 2000-03-22 2001-03-21 Production of recombinant blood clotting factors in human cell lines

Publications (3)

Publication Number Publication Date
BR0109494A BR0109494A (pt) 2002-12-10
BRPI0109494B1 BRPI0109494B1 (pt) 2021-05-11
BRPI0109494B8 true BRPI0109494B8 (pt) 2021-05-25

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0109494A BRPI0109494B8 (pt) 2000-03-22 2001-03-21 muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii

Country Status (28)

Country Link
US (1) US7572619B2 (enExample)
EP (2) EP1460131A3 (enExample)
JP (1) JP3894795B2 (enExample)
KR (1) KR100581574B1 (enExample)
CN (1) CN1454257B (enExample)
AT (1) ATE312176T1 (enExample)
AU (3) AU2001254715B2 (enExample)
BE (1) BE2014C077I2 (enExample)
BG (1) BG65930B1 (enExample)
BR (1) BRPI0109494B8 (enExample)
CA (1) CA2404163C (enExample)
CZ (1) CZ303929B6 (enExample)
DE (1) DE60115613T2 (enExample)
DK (1) DK1266006T3 (enExample)
EA (1) EA004317B1 (enExample)
EE (1) EE200200538A (enExample)
ES (1) ES2254403T3 (enExample)
FR (1) FR15C0003I2 (enExample)
HR (1) HRP20020767B1 (enExample)
HU (1) HU228091B1 (enExample)
IL (2) IL151857A0 (enExample)
MX (1) MXPA02009221A (enExample)
NO (1) NO330910B1 (enExample)
NZ (1) NZ521732A (enExample)
RS (1) RS50743B (enExample)
SI (1) SI1266006T1 (enExample)
SK (1) SK287706B6 (enExample)
WO (1) WO2001070968A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0109494B8 (pt) * 2000-03-22 2021-05-25 Octagene Gmbh muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
MXPA03002256A (es) * 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
ATE489105T1 (de) 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
DK2438931T3 (da) 2004-09-22 2013-12-02 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101120085B (zh) * 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
WO2008134665A1 (en) * 2007-04-26 2008-11-06 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2198870A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
AU2012257736B2 (en) 2011-05-13 2015-12-10 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2013057219A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Method for improving the stability of purified factor viii after reconstitution
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
GB201210357D0 (en) * 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
CN105025920A (zh) * 2013-01-24 2015-11-04 博尔托拉制药公司 具有因子Xa衍生物的组织因子途径抑制剂的抑制
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
SG10201802098UA (en) * 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
AU2019366942B2 (en) 2018-10-23 2025-10-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
DE3785102T2 (de) * 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
CA2135744A1 (en) * 1989-11-17 1991-05-18 Barbara Chapman Protein complexes having factor viii:c activity and production thereof
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FI923347A0 (fi) * 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
CA2162497A1 (en) * 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
EP0951544A2 (en) * 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP2002537311A (ja) 1999-02-19 2002-11-05 オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
BRPI0109494B8 (pt) * 2000-03-22 2021-05-25 Octagene Gmbh muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
FR15C0003I1 (fr) 2015-02-27
BG107152A (bg) 2003-06-30
SK287706B6 (en) 2011-07-06
JP3894795B2 (ja) 2007-03-22
WO2001070968A3 (en) 2001-12-13
EA200201008A1 (ru) 2003-02-27
IL151857A (en) 2010-05-31
WO2001070968A2 (en) 2001-09-27
DE60115613D1 (de) 2006-01-12
KR20030011079A (ko) 2003-02-06
EE200200538A (et) 2004-04-15
DE60115613T2 (de) 2006-08-24
HUP0300588A2 (hu) 2003-06-28
HRP20020767A2 (en) 2005-02-28
EP1460131A3 (en) 2005-06-01
DK1266006T3 (da) 2006-01-16
US20040023333A1 (en) 2004-02-05
CA2404163C (en) 2009-09-29
AU5471501A (en) 2001-10-03
BE2014C077I2 (enExample) 2020-01-30
ES2254403T3 (es) 2006-06-16
HUP0300588A3 (en) 2005-09-28
AU2006201848A1 (en) 2006-05-25
YU71002A (sh) 2005-11-28
AU2001254715B2 (en) 2006-02-02
EA004317B1 (ru) 2004-02-26
SK15042002A3 (sk) 2003-09-11
FR15C0003I2 (fr) 2015-11-20
JP2003530093A (ja) 2003-10-14
BRPI0109494B1 (pt) 2021-05-11
NO20024475L (no) 2002-11-20
NO330910B1 (no) 2011-08-15
IL151857A0 (en) 2003-04-10
BR0109494A (pt) 2002-12-10
EP1266006B1 (en) 2005-12-07
SI1266006T1 (sl) 2006-06-30
NZ521732A (en) 2004-05-28
RS50743B (sr) 2010-08-31
CN1454257B (zh) 2013-01-16
MXPA02009221A (es) 2005-07-25
EP1266006A2 (en) 2002-12-18
CN1454257A (zh) 2003-11-05
BG65930B1 (bg) 2010-05-31
HU228091B1 (en) 2012-10-29
CZ20023166A3 (cs) 2003-02-12
NO20024475D0 (no) 2002-09-19
ATE312176T1 (de) 2005-12-15
KR100581574B1 (ko) 2006-05-22
US7572619B2 (en) 2009-08-11
CA2404163A1 (en) 2001-09-27
CZ303929B6 (cs) 2013-07-03
HRP20020767B1 (hr) 2011-09-30
EP1460131A2 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
DE68917300T2 (de) Heilung von wunden.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
BR0309877A (pt) Peptìdeos estimuladores de tecido conectivo
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
BR9608019A (pt) Uma nova proteína e um processo para a preparação da mesma'
ATE265529T1 (de) Bmp-10 zusammensetzungen
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
BR0009074A (pt) Proteìna para bloquear adesão de plaqueta
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
EA021186B1 (ru) Композиции, включающие интерлейкин-1 и пептиды
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
KR890006815A (ko) 산성 섬유아세포 생장인자의 돌연변이체
BR9908096A (pt) Proteìna 3 da zona pelúcida humana (hzp3), ativa, recombinante
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
Lin et al. Granule proteins of the dental follicle and stellate reticulum inhibit tooth eruption and eyelid opening in postnatal rats
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: OCTAGENE GMBH (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060052755/RJ DE 17/04/2006.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: OCTAPHARMA BIOPHARMACEUTICALS GMBH (DE)

Free format text: NOME ALTERADO DE: OCTAGENE GMBH

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: OCTAPHARMA AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/03/2021